Retas Skyclavs was one of the biggest in 2023 for $7.3bn US by Biogen rare disease drug estimate 5,000 patients in US and $1.5bn sales 2030….. premium was only 60% on their share price at the time.
2591 ‘s potential patients with only current x 4 indications is x 10 (as per presentations) that of Skyclavs with scope for many more potentially…..
Retas deal x 10 is $10-15bn in sales 2030-2033 US only for the potential future of 2591 as a starting point. Likely $30 bn globally…
Fairly attractive asset.
Retas Skyclavs was one of the biggest in 2023 for $7.3bn US by...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.73 |
Change
-0.280(1.33%) |
Mkt cap ! $2.647B | |||
| Open | High | Low | Value | Volume |
| $20.87 | $21.19 | $20.70 | $6.213M | 297.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 5414 | $20.72 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.79 | 335 | 1 |
View Market Depth
| Last trade - 16.10pm 21/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$20.73 |
Change
-0.280 ( 1.22 %) |
||||
| Open | High | Low | Volume | ||
| $20.99 | $21.19 | $20.69 | 94423 | ||
| Last updated 15.59pm 21/05/2024 ? | |||||
| NEU (ASX) Chart |